MT-TP and metabolic dysfunction-associated steatotic liver disease: BBR selectively inhibits HFD-induced MTTP methylation to partially counteract HFD-induced MTTP dysregulation, which promotes normal levels of VLDL secretion in the liver, thereby reducing hepatic fat content and alleviating NAFLD (Chang et al., 2010).